About Thymosin Alpha-1 Reviews

What this site is

Thymosin Alpha-1 Reviews is an evidence-appraisal desk for the peer-reviewed research literature on Thymosin Alpha-1 (thymalfasin) — it weighs each study and reports it in plain, measured terms. No clinic or pharmacy stands behind it; no one here sees patients, prescribes, or supplies anything, and there is no product to buy. The work summarizes published science and cites every figure — it reports what the trials found, it does not diagnose, treat, or advise.

The "reviews" in our name is an evidence-appraisal stance, not a rating service and not a vendor signal. It means we weigh the published record — saying plainly what is established, what is suggestive, and what failed. We hold the strong results (chronic hepatitis B) apart from the negative ones (the null phase-3 sepsis trial), and we report findings as study-attributed, never upgrading "studied" to "proven."

How we read the record

Our editorial lens is immune tolerance and autoimmunity — the dual character of a peptide that both stimulates and regulates the immune system. We aim for accuracy first: Thymosin Alpha-1 is an immunomodulatory thymic peptide, not an anabolic or performance compound, and we keep it strictly distinct from the peptides it is confused with — thymosin beta-4 (the actin-binding peptide sold as TB-500), thymulin, thymopentin, thymalin, and its precursor prothymosin alpha. Every quantitative claim on this site maps to a numbered source on the references page.

What the modifier means

A domain modifier like "reviews" describes the position this publisher occupies relative to the literature — an appraisal desk — not a claim about services we offer. We do not diagnose, treat, prescribe, or sell. Thymosin Alpha-1 is not approved for marketing in the United States, and nothing here should be read as encouragement to obtain or use it outside of approved medical settings. We summarize research; readers make their own decisions with qualified professionals.